Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

Chronic cough is one of the most debilitating symptoms in patients with IPF. It is estimated
that over 80% of patients with IPF experience clinically significant cough. The impact of
chronic cough on QOL includes fatigue, embarrassment, anxiety, sleep disturbance,
hoarseness, incontinence, dizziness, vomiting, rib fractures, and severe dyspnea. There is
also some evidence that chronic cough may contribute to increased airway inflammation. In
IPF patients, significant oxygen desaturation often accompanies coughing episodes leading to
increased dyspnea, anxiety, and panic. Studies examining alternative therapeutic agents for
cough in IPF patients are scarce. Cough in patients with IPF is typically refractory to
traditional antitussive agents or corticosteroids.

Unfortunately, the side effects of corticosteroids combined with their lack of efficacy in
prevention of disease progression in IPF makes this a less desired treatment option.

Although opiates can be effective in controlling cough, issues of sedation, respiratory
depression and narcotic dependence are significant.

This is an open label, safety and efficacy pilot study of pomalidomide in 20 patients with
IPF. This study will determine both the tolerability and feasibility of pomalidomide for the
treatment of cough in this patient population.

Eligible patients will be selected from our Interstitial Lung Disease Clinic database which
consists of patients with ILD seen in our clinic since about 2004 who have signed informed
consent (previously approved by our Administrative Panel on Human Subjects in Medical
Research, protocol #14054). Those patients with IPF who describe the severity of their cough
as decreasing, or adversely affecting, their quality of life will be invited to participate
in the study.

SCREENING VISIT During this visit, the study will be fully reviewed with the patient, who
will already have received the consent form and discussed it by phone, or at a previous
clinic visit with the study coordinator and possibly the PI or Sub PI. At this visit the pt.
will undergo Informed Consent, bloodwork including Chem Panel with LFTs, CBC, History and
Physical Exam - MD, Vital Signs, Spirometry without Bronchodilator, Diffusion Capacity, 6
Minute Walk, EKG, Adverse Events, Cough Visual Analog Scale (VAS), Leicester Cough
Questionaire (LCQ), Cough-Specific Quality-of-Life Questionnaire (CQLQ),St. George
RespiratoryQuestionnaire (SGRQ), and dispensation of the Cough Symptom Diary (CSD).

If the patient continues to meet eligibility criteria, current cough suppressive agents will
be discontinued from days 1-14.

STUDY DAY 1, VISIT 1 History and Physical Exam - MD, Vital Signs, Adverse Events, Cough
Visual Analog Scale, LCQ, CQLQ and the SGRQ. The patient will then be given a 30 day supply
of 2mg capsules of pomalidomide with written instructions on dosing and instructions to call
the study center with any adverse reactions.

WEEK 1, Visit 2 Pt. will come to study site for safety labs, and assessment of adverse
events and any changes in medications.

WEEK 2, VISIT 3 The patient will return to the clinic to be assessed for potential adverse
reactions and to have safety laboratory work done.

WEEKS 4, 8, and 12 (Visits 4,6, and 8) The participant will return to the study center and
undergo physical exam, vital signs, assessment of adverse events, and self-completion of the
VAS, LCQ, and the CQLQ. Every two weeks (Visits 2, 4, and 6) the patient will also undergo
safety laboratory testing which can either be done at Stanford or at a local lab. As part of
routine care, we will obtain spirometry and 6MWT at the start and end of study (week 0 and
week 12 ± 2 weeks). If there are abnormalities in the patient's labs at week 2 we will
either withdraw the patient from the study or down- titrate their dose depending on the
severity of lab abnormality.

A 30 day supply of 2mg capsules of pomalidomide will be dispensed at Week 4 and 8.

The patient will undergo a 2 week taper to 1 mg/day of study drug at week 12 to off drug by
wk. 14, and will have a return follow up visit at week 18 for assessment of adverse events,
history and physical exam, lab work including pregnancy test, and completion of all four
questionnaires.

Patients responding by meeting the established minimally clinically important difference for
the CQLQ as well as having demonstrated safety tolerance by laboratory tests and physician
exam and who wish to remain in the study may do so for an additional 9 months at the
discretion of the Protocol Director. These participants will not undergo taper at week 12
and will be re-supplied on a monthly basis until week 48 at which time they will taper to
off drug over 2 weeks.

The Visit Schedule for the extension study is the same as the initial 3 months with the
exception that safety laboratory blood work is done monthly instead of every two weeks.

Inclusion Criteria:

1. Understand and voluntarily sign an informed consent form.

2. >18 and < 75 years old at the time of signing the informed consent form.

3. Able to adhere to the study visit schedule and other protocol requirements.

4. Have a diagnosis of Idiopathic Pulmonary Fibrosis in accordance to American Thoracic
Society guidelines.

5. Persistent cough:

• as defined by a cough that adversely affects the patient's quality of life and has
been present for at least 3 months.

6. Laboratory test results within these ranges:

- Absolute neutrophil count >2 x 103/ul

- Platelet count >100,000 /mm³

- Serum creatinine < 2.0 mg/dL

- Total bilirubin < 1.5 mg/dL

7. Diffusion capacity > 25%predicted

8. Forced vital capacity <80% predicted • AST (SGOT) and ALT (SGPT) < 2 x ULN

8. Able to take aspirin (81 or 325 mg) daily as prophylactic anti-coagulation (patients
intolerant to ASA may use warfarin or low molecular weight heparin).

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

2. Females of child-bearing potential defined as a sexually mature woman who: 1) has not
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
postmenopausal for at least 24 consecutive months (i.e., has had menses at any time
in the preceding 24 consecutive months).

3. Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

4. Use of any other experimental drug or therapy within 28 days of baseline.

5. Known hypersensitivity to thalidomide or lenalidomide.

6. Any prior use of thalidomide, lenalidomide or pomalidomide (CC-4047).

7. Known positive for HIV or infectious hepatitis, type A, B or C.

8. History of deep venous thrombosis

9. History of pulmonary embolism

10. Use of the following anti-tussive agents must be discontinued 14 days prior to their
baseline visit. -

1. prednisone 2. narcotic anti-tussives 3. baclofen 4. neurontin 11. Treatment for
infection or acute exacerbation within past 3 months